

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) dated May 12, 2026 (the “**Announcement**”), in relation to the receipt of a case filing notice from the China Securities Regulatory Commission by Mr. Ye Xiaoping (“**Mr. Ye**”) and Ms. Cao Xiaochun (“**Ms. Cao**”), directors and controlling shareholders of the Company. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Company has noted that there is speculation in the market as to whether Mr. Ye and Ms. Cao had made public announcements and disclosures as required. After making reasonable inquiries regarding the Company under relevant circumstances, the Company hereby clarifies and emphasizes that the subject matter of the investigation pertains to information disclosures related to the historical shareholding changes of Mr. Ye and Ms. Cao, and the two controlling shareholders have made corresponding announcements on all previous reduction of shareholding, and the shareholding information was also disclosed in the Company’s periodic reports. The information disclosure obligors have also additionally supplemented the disclosure by publishing the Brief Report on Equity Change (《簡式權益變動報告》). The aforementioned matters are unrelated to the Company’s business operations and will not affect the Company’s normal business operations.

Any information concerning the Group should only be based on the Company's official announcements. The shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, May 13, 2026

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.